UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 173

Sortiert nach

Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report

Journal of medical case reports, 2021-02, Vol.15 (1), p.90-6, Article 90

2021

Volltextzugriff (PDF)

Generalized megaviscera of lupus： Refractory intestinal pseudo-obstruction, ureterohydronephrosis and megacholedochus

World journal of gastroenterology : WJG, 2009-07, Vol.15 (28), p.3555-3559

2009

Volltextzugriff (PDF)

B09 CARTITUDE‐2 COHORT B 18‐MONTH FOLLOW‐UP: CILTACABTAGENE AUTOLEUCEL (CILTA‐CEL), A BCMA‐DIRECTED CAR‐T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY

HemaSphere, 2023-05, Vol.7 (S2), p.8-8

2023

Volltextzugriff (PDF)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA‐CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON‐CELLULAR ANTI‐B‐CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY

HemaSphere, 2023-05, Vol.7 (S2), p.25-26

2023

Volltextzugriff (PDF)

P23 EMAGINE/CARTITUDE‐6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT‐ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

HemaSphere, 2023-05, Vol.7 (S2), p.22-23

2023

Volltextzugriff (PDF)

P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL‐WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE‐1 AND THE EMMY FRENCH COHORT

HemaSphere, 2022-06, Vol.6 (Suppl), p.795-796

2022

Volltextzugriff (PDF)

USPSTF Update of Guidelines on Early Detection of Prostate Cancer

Missouri medicine, 2018-07, Vol.115 (4), p.337-337

Madduri, Sivaprasad D

2018

Volltextzugriff (PDF)

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA‐DIRECTED CAR‐T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2‐YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE‐1 STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.851-852

2022

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1–3 PRIOR LINES OF THERAPY: CARTITUDE-2 PHASE 2 STUDY

Hematology, Transfusion and Cell Therapy, 2021-10, Vol.43, p.S255-S255

2021

Volltextzugriff (PDF)

INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2

Hematology, Transfusion and Cell Therapy, 2021-10, Vol.43, p.S263-S264

2021

Volltextzugriff (PDF)

UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Hematology, Transfusion and Cell Therapy, 2021-10, Vol.43, p.S272-S272

2021

Volltextzugriff (PDF)

UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

Hematology, Transfusion and Cell Therapy, 2020-11, Vol.42, p.279-280

2020

Volltextzugriff (PDF)

Mechanical axial flow blood pump to support cavopulmonary circulation

International journal of artificial organs, 2008-11, Vol.31 (11), p.970-982

2008

Volltextzugriff (PDF)

Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project

Blood, 2017, Vol.130, p.325-325

2017

Volltextzugriff (PDF)

The effect of novel therapies in high-molecular-risk multiple myeloma

Clinical advances in hematology & oncology, 2017-11, Vol.15 (11), p.870-879

2017

Volltextzugriff (PDF)

Taking care of cancer patients: beyond science and technology

Missouri medicine, 2009-01, Vol.106 (1), p.19

Madduri, Sivaprasad D

2009

Volltextzugriff (PDF)

Can In-Silico Computational Virtual Screening of Fragment Libraries Model In-Vitro Biophysical Screening Methods with Similar Results to Identify Novel RNA-Binding Chemical Matter for Treatment of Myotonic Dystrophy?

Madduri, Ameya D

2023

Volltextzugriff (PDF)

Doctor with attitude. The doctor was in, but I wish he wasn't

Missouri medicine, 2006-11, Vol.103 (6), p.595

Madduri, Sivaprasad D

2006

Volltextzugriff (PDF)

Anti-BCMA-CAR-T-Zell-Therapie bei einem Patienten mit rezidiviertem und refraktärem Multiplen Myelom nach einer COVID-19-Infektion: ein Fallbericht

Kompass Onkologie, 2022-02, Vol.9 (1), p.40-45

2022

Volltextzugriff (PDF)

After two years, did Viagra live up to its expectations?

Missouri medicine, 2001-06, Vol.98 (6), p.243

Madduri, S D

2001

Volltextzugriff (PDF)

PET-Computed Tomography in Myeloma

PET clinics, 2019-07, Vol.14 (3), p.411-418

2019

Volltextzugriff (PDF)

Anti-BCMA-CAR-T-Zell-Therapie bei einem Patienten mit rezidiviertem und refraktärem Multiplen Myelom nach einer COVID-19-Infektion: ein Fallbericht

Kompass Onkologie, 2022-02, Vol.9 (1), p.40-45

2022

Volltextzugriff (PDF)

Taking care of cancer patients; beyond science and technology

Missouri medicine, 1999-12, Vol.96 (12), p.553

Madduri, S D

1999

Volltextzugriff (PDF)

Is health care a right?

Missouri medicine, 1996-04, Vol.93 (4), p.180

Madduri, S D

1996

Volltextzugriff (PDF)

Doctors are people too

Missouri medicine, 1994-11, Vol.91 (11), p.690

Madduri, S D

1994

Volltextzugriff (PDF)

1 – 25 von 173

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(140)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report

Generalized megaviscera of lupus： Refractory intestinal pseudo-obstruction, ureterohydronephrosis and megacholedochus

B09 CARTITUDE‐2 COHORT B 18‐MONTH FOLLOW‐UP: CILTACABTAGENE AUTOLEUCEL (CILTA‐CEL), A BCMA‐DIRECTED CAR‐T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA‐CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON‐CELLULAR ANTI‐B‐CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY

P23 EMAGINE/CARTITUDE‐6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT‐ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL‐WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE‐1 AND THE EMMY FRENCH COHORT

USPSTF Update of Guidelines on Early Detection of Prostate Cancer

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA‐DIRECTED CAR‐T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2‐YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE‐1 STUDY

EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1–3 PRIOR LINES OF THERAPY: CARTITUDE-2 PHASE 2 STUDY

INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-2

UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

Mechanical axial flow blood pump to support cavopulmonary circulation

Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project

The effect of novel therapies in high-molecular-risk multiple myeloma

Taking care of cancer patients: beyond science and technology

Can In-Silico Computational Virtual Screening of Fragment Libraries Model In-Vitro Biophysical Screening Methods with Similar Results to Identify Novel RNA-Binding Chemical Matter for Treatment of Myotonic Dystrophy?

Doctor with attitude. The doctor was in, but I wish he wasn't

Anti-BCMA-CAR-T-Zell-Therapie bei einem Patienten mit rezidiviertem und refraktärem Multiplen Myelom nach einer COVID-19-Infektion: ein Fallbericht

After two years, did Viagra live up to its expectations?

PET-Computed Tomography in Myeloma

Anti-BCMA-CAR-T-Zell-Therapie bei einem Patienten mit rezidiviertem und refraktärem Multiplen Myelom nach einer COVID-19-Infektion: ein Fallbericht

Taking care of cancer patients; beyond science and technology

Is health care a right?

Doctors are people too

Suchergebnisse filtern